![Euroapi Company Header](https://www.pharmacompass.com/image/flap/euroapi-corp-ad-w30-desktop-header-1-2gif-57087.gif)
![Euroapi Company Header](https://www.pharmacompass.com/image/flap/euro-api-mob-header-w30gif-19381.gif)
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
https://www.prnewswire.com/news-releases/bio-thera-solutions-receives-positive-chmp-opinion-for-avzivi-bevacizumab-a-biosimilar-referencing-avastin-302161771.html
https://www.prnewswire.com/news-releases/bio-thera-solutions-presents-clinical-data-for-bat8006-folate-receptor-alpha-adc-at-the-2024-american-society-of-clinical-oncology-asco-annual-meeting-302161233.html
https://www.prnewswire.com/news-releases/bio-thera-and-stada-reach-exclusive-agreement-for-bat2506-a-proposed-golimumab-biosimilar-in-the-eu-and-uk-302156882.html
https://www.prnewswire.com/news-releases/bio-thera-solutions-receives-ind-clearance-from-us-fda-to-initiate-a-phase-ii-study-for-bat8006-an-innovative-antibody-drug-conjugate-targeting-folate-receptor--302098092.html
https://www.prnewswire.com/news-releases/bio-thera-solutions-partners-with-steincares-to-market-two-biosimilars-in-latam-302091434.html
https://www.prnewswire.com/news-releases/bio-thera-solutions-announces-initiation-of-phase-ib--iia-clinical-trial-for-bat6026-a-monoclonal-antibody-targeting-ox40-in-patients-with-moderate-to-severe-atopic-dermatitis-302050451.html
https://www.prnewswire.com/news-releases/fda-approves-bio-thera-solutions-avzivi-bevacizumab-tnjn-a-biosimilar-referencing-avastin-302009433.html
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761198
https://www.prnewswire.com/news-releases/fda-approves-tofidence-tocilizumab-bavi-a-biosimilar-of-actemra-developed-by-bio-thera-solutions-301950199.html